Kansas City Launches First Pediatric Cancer Treatment Center

Kansas City is about to become a trailblazer in precision cancer treatment, especially for kids who need it most.

The University of Kansas Health System, the University of Kansas Medical Center, Children's Mercy, and BAMF Health announced their partnership in February 2026 to create a fully integrated theranostics research and treatment center. It's one of the first of its kind in the United States.

Theranostics combines diagnostics and treatment into a single, targeted approach. Instead of traditional chemotherapy that affects the whole body, this precision medicine uses molecular imaging to find cancer cells and deliver treatment directly to them, making care less invasive and more effective.

The real game changer? This center is designed with children in mind from day one.

While theranostics is currently used mostly for adult patients, Children's Mercy is among the first pediatric hospital systems in the country to invest early in this technology. That means children won't have to wait years to access breakthrough treatments that could save their lives with fewer harsh side effects.

The center will house everything under one roof: diagnostic tools, molecular imaging equipment, radiopharmaceutical production facilities, and targeted therapy programs. This integrated approach streamlines care and speeds up the journey from diagnosis to treatment.

The Ripple Effect

The collaboration strengthens Kansas City's capacity to run clinical trials and develop new treatments that will help patients far beyond the region. By bringing together multiple health systems, the partnership pools resources, expertise, and research capabilities that no single institution could achieve alone.

Families traveling to Kansas City for treatment will find a coordinated care team ready to guide them through every step. The center positions the region as a national destination for healthcare innovation, potentially attracting more medical research investments and job opportunities.

Bob Page, president and CEO of The University of Kansas Health System, called theranostics "the next forefront of precision medical care and research." The collaboration will advance both discovery and treatment while driving economic growth through healthcare innovation.

For children facing cancer diagnoses, this means access to tomorrow's treatments today, right in their own backyard.